X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ASTRAZENECA PHARMA - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA ASTRAZENECA PHARMA AUROBINDO PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 15.4 83.8 18.4% View Chart
P/BV x 3.1 18.5 16.9% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 AUROBINDO PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
ASTRAZENECA PHARMA
Mar-18
AUROBINDO PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs8091,278 63.3%   
Low Rs504883 57.1%   
Sales per share (Unadj.) Rs281.1228.4 123.1%  
Earnings per share (Unadj.) Rs41.410.4 399.0%  
Cash flow per share (Unadj.) Rs50.916.3 312.9%  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs199.498.8 201.8%  
Shares outstanding (eoy) m585.8825.00 2,343.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.34.7 49.4%   
Avg P/E ratio x15.9104.2 15.2%  
P/CF ratio (eoy) x12.966.4 19.4%  
Price / Book Value ratio x3.310.9 30.1%  
Dividend payout %6.00-   
Avg Mkt Cap Rs m384,63027,008 1,424.2%   
No. of employees `00017.31.4 1,278.2%   
Total wages/salary Rs m21,3081,535 1,387.9%   
Avg. sales/employee Rs Th9,500.74,210.9 225.6%   
Avg. wages/employee Rs Th1,229.41,132.2 108.6%   
Avg. net profit/employee Rs Th1,397.9191.1 731.6%   
INCOME DATA
Net Sales Rs m164,6665,710 2,883.8%  
Other income Rs m1,020123 832.5%   
Total revenues Rs m165,6865,833 2,840.7%   
Gross profit Rs m37,718463 8,148.1%  
Depreciation Rs m5,580147 3,785.4%   
Interest Rs m7770-   
Profit before tax Rs m32,380438 7,392.8%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,183179 4,573.9%   
Profit after tax Rs m24,229259 9,351.3%  
Gross profit margin %22.98.1 282.5%  
Effective tax rate %25.340.8 61.9%   
Net profit margin %14.74.5 324.3%  
BALANCE SHEET DATA
Current assets Rs m121,8783,209 3,797.8%   
Current liabilities Rs m86,8062,070 4,194.5%   
Net working cap to sales %21.320.0 106.7%  
Current ratio x1.41.6 90.5%  
Inventory Days Days13072 179.5%  
Debtors Days Days6835 195.8%  
Net fixed assets Rs m81,037790 10,254.0%   
Share capital Rs m58650 1,171.8%   
"Free" reserves Rs m116,2182,419 4,803.8%   
Net worth Rs m116,8042,469 4,730.3%   
Long term debt Rs m4,5120-   
Total assets Rs m211,0524,605 4,582.7%  
Interest coverage x42.7NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.81.2 62.9%   
Return on assets %11.85.6 210.6%  
Return on equity %20.710.5 197.7%  
Return on capital %27.417.7 154.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,727300 26,949.5%   
Fx outflow Rs m34,7002,015 1,722.2%   
Net fx Rs m46,027-1,715 -2,683.2%   
CASH FLOW
From Operations Rs m19,54888 22,239.1%  
From Investments Rs m-19,570-94 20,907.6%  
From Financial Activity Rs m8,642NA-  
Net Cashflow Rs m8,922-6 -156,528.1%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 8.0 0.3 2,650.0%  
FIIs % 27.7 15.7 176.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 9.1 112.1%  
Shareholders   69,601 12,856 541.4%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   AJANTA PHARMA  GLENMARK PHARMA  SUN PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 491 Points, India's Rising Trade Deficit, and Top Stocks in Action(Pre-Open)

After opening the day marginally lower, share markets in India witnessed negative trading activity throughout Monday and ended deep in the red.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)

Jun 6, 2019

Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)

Jun 10, 2019

The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jun 17, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS